FGFR1 and non-small cell lung carcinoma: Collectively, these results revealed that C1632 simultaneously suppressed LIN28 expression and blocked FGFR1 signalling and that C1632 is able to rapidly inhibit migration and proliferation of NSCLC cells, regardless of drug resistance, in vivo, indicating that it has the potential to act as an anticancer agent for NSCLC treatment.